People on Medicare may in 2026 see prices drop for 10 medicines, including pricey diabetes, cancer, blood clot, and arthritis treatments, if advocates for federal drug-price negotiations can implement their plans amid tough opposition. The Biden administration revealed the first 10 drugs selected for direct Medicare price negotiations in accordance with a process mandated by the Inflation Reduction Act of 2022. The 10 selected medicines are as follows: Eliquis (generic name: apixaban), Jardiance (generic name: empagliflozin), Xarelto (generic name: rivaroxaban), Januvia (generic name: sitagliptin), Farxiga (generic name: dapagliflozin), Entresto (generic name: sacubitril/valsartan), Enbrel( generic name: etanercept), Imbruvica (generic name: ibrutinib), Stelara (generic name: ustekinumab), Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill.
Link: Medscape (August 2023)
